Martin Glensbjerg takes up new position at ChemoMetec
December 20 2023 - 8:35AM
Martin Glensbjerg takes up new position at ChemoMetec
ANNOUNCEMENT NO. 248
20 December 2023
Martin Glensbjerg takes up a new role in
ChemoMetec
COO and deputy chairman of the board Martin
Glensbjerg has decided to step down in ChemoMetec to pass the baton
on to the next generation.
From 1 February 2024 until the end of 2024, he
will act as Senior Advisor with reference to CEO Rasmus Kofoed.
Martin Glensbjerg continues as deputy chairman of the board. In his
new role, Martin Glensbjerg will, among other things, participate
in the update of ChemoMetec's strategy and also contribute to
ensuring a successful anchoring and launch of the upcoming new
products, including XcytoMatic 40 and XcytoMatic 30.
At the same time, Martin Helbo Behrens, Deputy
COO, is appointed COO, and Bo Melholt Nielsen, Physicist &
Project Manager, Chief R&D Officer. Both Martin Helbo Behrens
and Bo Melholt Nielsen have been employed at ChemoMetec for a
number of years. Before joining as Deputy COO earlier this year,
Martin Helbo Behrens was CFO and COO in ChemoMetec's American
subsidiary and was part of Group Finance before that. Bo Melholt
Nielsen has a strong academic and professional background in
physics, especially quantum optics, and as project manager for the
development of XcytoMatic 40 and XcytoMatic 30 he has been a
significant driving force behind the development of the new
generation of products.
Martin Glensbjerg was one of three co-founders
when ChemoMetec was established in 1997, and since then he has held
a leading position in the company and has made a significant
contribution to ensuring that ChemoMetec has today achieved an
attractive global market position.
In connection with Martin Glensbjerg's decision
chairman of the board, Niels Thestrup, says: "Martin has played a
very special role in ChemoMetec, and his eye for combining
innovation and business has been a decisive element in building a
well-functioning business model – and for the possibility to grow
from a start-up to a largecap company. I understand Martin's
decision and the background to it. Over a period of time, we have
developed several new products which will be launched in the coming
period, and we are thus moving into a new phase in the company's
life. With the new generation of leaders and exciting products, it
is our ambition to ensure ChemoMetec an even stronger position in
existing markets and at the same time provide ChemoMetec the
opportunity to move into new attractive markets".
For further information
Chairman of the Board Niels ThestrupPhone: (+45)
3370 2000
CEO Rasmus KofoedPhone: (+45) 2672
6819
About ChemoMetec A/S
ChemoMetec develops, manufactures and markets
instruments for cell counting and a wide range of other
measurements. ChemoMetec’s instruments are marketed to the
pharmaceutical, biotech and agricultural industries worldwide.
ChemoMetec’s customers include some of the world’s leading
pharmaceutical companies, such as Novartis, Novo Nordisk, H.
Lundbeck, Merck, AstraZeneca and Johnson & Johnson.
ChemoMetec was founded in 1997 and is listed on
the Nasdaq Copenhagen stock exchange. For more information, go to
www.chemometec.com
Chemometec AS (TG:CHY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Chemometec AS (TG:CHY)
Historical Stock Chart
From Jul 2023 to Jul 2024